Clinical Drug Investigation

, Volume 37, Issue 6, pp 541–549 | Cite as

A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting

  • Åse Björstad
  • Lars-Olaf Cardell
  • Julie Hahn-Pedersen
  • Mikael Svärd
Original Research Article


Background and Objectives

In Sweden, approximately 6% of children and 10% of adults suffer from house dust mite (HDM) allergy with symptoms of allergic rhinitis and allergic asthma. Treatment is aimed at reducing HDM exposure and to control the symptoms of allergic rhinitis and allergic asthma by symptom-relieving pharmacotherapy. This pharmacotherapy is often effective, but some patients remain inadequately controlled. For these patients, allergy immunotherapy (AIT, subcutaneous or sublingual) with repeated administration of HDM allergen should be considered. The objective of this study was to compare the costs for sublingual AIT (SLIT; SQ® SLIT-tablet) to the costs for subcutaneous AIT (SCIT; SQ® SCIT) for the treatment of HDM allergy in a cost-minimisation analysis (CMA).


The CMA included resources (and costs) for treatment, healthcare visits, travelling and lost productivity. Resource use based on Swedish clinical treatment practice and costs were obtained from medical price lists. Analyses were conducted from the societal, as well as healthcare perspective, by use of a time horizon of 3 years.


The results show that SQ® SLIT-tablet is a cost-saving treatment as compared to SQ® SCIT for the treatment of HDM allergy (€6800 over 3 years). The results are mainly driven by the cost of healthcare visits and the frequency of SCIT administrations.


In conclusion, cost-savings of €6800 over 3 years are expected from treating HDM allergy with SQ® SLIT-tablet as compared to SQ® SCIT, including costs for treatment, healthcare visits, travelling and lost productivity. The reduced number of healthcare visits compensates for higher medication costs.


Allergic Rhinitis Allergic Asthma House Dust Mite Sublingual Immunotherapy Healthcare Visit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards


This study was funded by ALK Nordic A/S.

Conflicts of interest

Åse Björstad is employed by Nordic Health Economics AB, which received a fee for services related to the development and execution of this study, and for the analysis, and reporting of its results. Lars-Olaf Cardell has received grants, consulting honorariums, travel grants and an honorarium for his contributions to evaluating this study and to the development of this manuscript, all from ALK. Julie Hahn-Pedersen was an employee of ALK during development of this manuscript and has stock options in ALK. Mikael Svärd is employed by ALK.


  1. 1.
    Compalati E, Ridolo E, Passalacqua G, Braido F, Villa E, Canonica GW. The link between allergic rhinitis and asthma: the united airways disease. Expert Rev Clin Immunol. 2010;6(3):413–23. doi: 10.1586/eci.10.15.CrossRefPubMedGoogle Scholar
  2. 2.
    Feng CH, Miller MD, Simon RA. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):187–90. doi: 10.2500/ajra.2012.26.3762.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Fiocchi A, Fox AT. Preventing progression of allergic rhinitis: the role of specific immunotherapy. Arch Dis Child Educ Pract Ed. 2011;96(3):91–100. doi: 10.1136/adc.2010.183095.CrossRefPubMedGoogle Scholar
  4. 4.
    Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.CrossRefPubMedGoogle Scholar
  5. 5.
    Global Initiative for Asthma (GINA). 2016 GINA Report, Global Strategy for Asthma Management and Prevention. 2016. Accessed 16 August 2016.
  6. 6.
    Chivato T, Valovirta E, Dahl R, de Monchy J, Bloch Thomsen A, Palkonen S, et al. Allergy, living and learning: diagnosis and treatment of allergic respiratory diseases in Europe. J Investig Allergol Clin Immunol. 2012;22(3):168–79.PubMedGoogle Scholar
  7. 7.
    Calderon MA, Linneberg A, Kleine-Tebbe J, De Blay F, Fernandez Hernandez, de Rojas D, Virchow JC, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38–48. doi: 10.1016/j.jaci.2014.10.012.CrossRefPubMedGoogle Scholar
  8. 8.
    Astma- och Allergiförbundet. Allergifakta 2015. 2015. Accessed 4 May 2016. 
  9. 9.
    Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin. 2004;20(3):305–17. doi: 10.1185/030079903125003053.CrossRefPubMedGoogle Scholar
  10. 10.
    Goeman DP, Aroni RA, Stewart K, Sawyer SM, Thien FC, Abramson MJ, et al. Patients’ views of the burden of asthma: a qualitative study. Med J Aust. 2002;177(6):295–9.PubMedGoogle Scholar
  11. 11.
    Cardell LO, Olsson P, Andersson M, Welin KO, Svensson J, Tennvall GR, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. doi: 10.1038/npjpcrm.2015.82.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jansson SA, Ronmark E, Forsberg B, Lofgren C, Lindberg A, Lundback B. The economic consequences of asthma among adults in Sweden. Respir Med. 2007;101(11):2263–70. doi: 10.1016/j.rmed.2007.06.029.CrossRefPubMedGoogle Scholar
  13. 13.
    Kardos P, Wittchen HU, Muhlig S, Ritz T, Buhl R, Rabe K, et al. Controlled and uncontrolled allergic asthma in routine respiratory specialist care—a clinical-epidemiological study in Germany. Curr Med Res Opin. 2011;27(9):1835–47. doi: 10.1185/03007995.2011.606805.CrossRefPubMedGoogle Scholar
  14. 14.
    Valero A, Justicia JL, Vidal C, Rodriguez V, Munoz R, Garcia MA. Diagnosis and treatment of allergic rhinitis due to house-dust mites in Spain. Am J Rhinol Allergy. 2012;26(1):23–6. doi: 10.2500/ajra.2012.26.3695.CrossRefPubMedGoogle Scholar
  15. 15.
    Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14(4):363–70. doi: 10.1097/ACI.0000000000000084.CrossRefPubMedGoogle Scholar
  16. 16.
    Ronborg S, Johnsen CR, Theilgaard S, Winther A, Hahn-Pedersen J, Andreasen JN, et al. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark. J Med Econ. 2016;. doi: 10.3111/13696998.2016.1158718.PubMedGoogle Scholar
  17. 17.
    Emminger W, Smeenk F, Guzik T, Dyczek A, Fejerskov P, Brodersen R et al. Abstract 417 The SQ HDM SLIT-tablet is well-tolerated in respiratory allergic disease; results from 2 DBPC phase III trials (MERIT and MITRA). European Academy of Allergy and Clinical Immunology Congress 2014. Copenhagen, Denmark; 2014. p. 111–99.Google Scholar
  18. 18.
    Hernández D, Mosbech H, Dichmann R, Grønager P, Riis B, Durham S. Abstract 421 SQ HDM SLIT-tablet induces significant immunomodulatory response; results from a DBPC phase III trial (MITRA). European Academy of Allergy and Clinical Immunology Congress 2014; Copenhagen, Denmark. Allergy. 2014. p. 111–99.Google Scholar
  19. 19.
    Demoly P, Decot E, Lozovskis V, Rehm D, Tommerup L, Kleine-Tebbe J. Abstract 415 Effective treatment of house dust mite (HDM) allergic rhinitis with the SQ HDM SLIT-tablet; results from a DBPC phase III trial (MERIT). European Academy of Allergy and Clinical Immunology Congress 2014; Copenhagen, Denmark. Allergy. 2014. p. 111–99.Google Scholar
  20. 20.
    Virchow J, Backer V, Kuna P, Prieto L, Villesen H, de Blay F. Abstract 414 SQ HDM SLIT-tablet is effective in the treatment of allergic asth-ma; results from a DBPC phase III trial (MITRA). European Academy of Allergy and Clinical Immunology Congress 2014; Copenhagen, Denmark. Allergy. 2014. p. 111–99.Google Scholar
  21. 21.
    Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69(7):854–67. doi: 10.1111/all.12383.CrossRefPubMedGoogle Scholar
  22. 22.
    Horak F, Maloney J, Nelson S, Bernstein D, Li Z, Zieglmayer P et al. Abstract 1778 Onset of action of house dust mite sublingual immunotherapy tab-let (SLIT-T) using an environmental exposure chamber. European Academy of Allergy and Clinical Immunology Congress 2014; Copenhagen, Denmark. Allergy. 2014. p. 111–99.Google Scholar
  23. 23.
    Klimek L, Mosbech H, Zieglmayer P, Rehm D, Stage BS, Demoly P. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Rev Clin Immunol. 2016;12(4):369–77. doi: 10.1586/1744666X.2016.1144473.CrossRefPubMedGoogle Scholar
  24. 24.
    Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2(2):144–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Mosbech H, Deckelmann R, de Blay F, Pastorello EA, Trebas-Pietras E, Andres LP, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134(3):568–75. doi: 10.1016/j.jaci.2014.03.019.CrossRefPubMedGoogle Scholar
  26. 26.
    Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi: 10.1186/1939-4551-7-6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Dranitsaris G, Ellis AK. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. J Eval Clin Pract. 2014;20(3):225–38. doi: 10.1111/jep.12112.CrossRefPubMedGoogle Scholar
  28. 28.
    Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. J Allergy Clin Immunol Pract. 2015;3(2):256–66. doi: 10.1016/j.jaip.2014.09.018.CrossRefPubMedGoogle Scholar
  29. 29.
    Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131(5):1361–6. doi: 10.1016/j.jaci.2013.02.013.CrossRefPubMedGoogle Scholar
  30. 30.
    Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):1–322. doi: 10.3310/hta17270.CrossRefGoogle Scholar
  31. 31.
    Chelladurai Y, Lin SY. Effectiveness of subcutaneous versus sublingual immunotherapy for allergic rhinitis: current update. Curr Opin Otolaryngol Head Neck Surg. 2014;22(3):211–5. doi: 10.1097/moo.0000000000000045.CrossRefPubMedGoogle Scholar
  32. 32.
    Chelladurai Y, Suarez-Cuervo C, Erekosima N, Kim JM, Ramanathan M, Segal JB, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract. 2013;1(4):361–9. doi: 10.1016/j.jaip.2013.04.005.CrossRefPubMedGoogle Scholar
  33. 33.
    Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130(5):1097–107. doi: 10.1016/j.jaci.2012.08.012.CrossRefPubMedGoogle Scholar
  34. 34.
    Produktresumé Acarizax. 2015. Accessed 9 May 2016. 
  35. 35.
    Produktresumé Alutard SQ 2-Dermatophagoides Kvalster. 2013. Accessed 11 May 2016. 
  36. 36.
    World Health Organisation. World Health Survey—Report of Sweden. 2003. Accessed 11 May 2016. 
  37. 37.
    Statistikdatabas för läkemedel [database on the Internet]2015. Available from: Accessed 12 May 2015.
  38. 38.
    Västra sjukvårdsregionen—Samverkansnämnden. Utomlänspriser 2015. 2015. %C3%A4mnden/Utoml %C3%A4nsprislista %202015.pdf. Accessed 9 May 2015.
  39. 39.
    Södra Regionvårdsnämnden. Regionala priser och ersättningar för södra sjukvårdsregionen 2015. 2015. %20regionvardsnamnden/prislista/2015/helaprislistan2015.pdf. Accessed 9 May 2015.
  40. 40.
    Genomsnittlig månadslön efter sektor 1992–2013 [database on the Internet] 2014. Available from: Accessed 12 May 2015.
  41. 41.
  42. 42.
    Samverkansnämnden Stockholm—Gotland. Utomlänsprislista sluten och öppenvård 2015. 2015. Accessed 9 May 2015.
  43. 43.
    Skatteverket. Snabbfakta om skatter—Trakatamente och bilersättningar—Från och med inkomståret 2013. 2015. Accessed 9 May 2016.
  44. 44.
    Tandvårds- och läkemedelsförmånsverket. Läkemedelsförmånsnämndens allmänna råd om ekonomiska utvärderingar. LFNAR. 2003;2003:2.Google Scholar
  45. 45.
    Tandvårds- och läkemedelsförmånsverket. Beslut Grazax. 2504/20112013. 2013. Accessed 16 Aug 2016.  
  46. 46.
    Bahceciler NN, Babayigit Hocaoglu A, Galip N. A milestone in house dust-mite-allergen immunotherapy: the new sublingual tablet S-524101 (actair). Expert Rev Vaccines. 2014;13(12):1427–38. doi: 10.1586/14760584.2014.972949.CrossRefPubMedGoogle Scholar
  47. 47.
    Aasbjerg K, Dalhoff KP, Backer V. Adverse events during immunotherapy against grass pollen-induced allergic rhinitis—differences between subcutaneous and sublingual treatment. Basic Clin Pharmacol Toxicol. 2015;117(2):73–84. doi: 10.1111/bcpt.12416.CrossRefPubMedGoogle Scholar
  48. 48.
    Norgaard Andreasen J, Lawton S, Boberg Baech S, Svärd M. Abstract 208 Compliance and persistence to grass immunotherapy treatment is comparable for allergy immunotherapy tablets and subcutaneous immunotherapy: a Swedish registry study. XXII World Allergy Congress. 2012.Google Scholar
  49. 49.
    Sieber J, De Geest S, Shah-Hosseini K, Mosges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin. 2011;27(4):855–61. doi: 10.1185/03007995.2011.559538.CrossRefPubMedGoogle Scholar
  50. 50.
    Kiel MA, Roder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Molken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353–60. doi: 10.1016/j.jaci.2013.03.013.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Nordic Health Economics ABGothenburgSweden
  2. 2.Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and TechnologyKarolinska InstitutetStockholmSweden
  3. 3.Department of Ear, Nose and Throat DiseasesKarolinska University HospitalStockholmSweden
  4. 4.ALKHørsholmDenmark
  5. 5.ALKKungsbackaSweden

Personalised recommendations